| Description |
Alzheimer's disease is a neurodegenerative disease accompanied by cognitive dysfunction and behavioral abnormalities. According to literature reports, the pathological changes of the brain are far earlier than the clinical manifestations of Alzheimer's disease patients, so it is necessary to find effective drugs to prevent AD and carry out preventive treatment. Urine, which is not regulated by homeostasis mechanism, is rich in systemic changes and can detect small changes in the body, making it a good source of disease biomarkers. Triagonist has been reported to have the potential to treat AD. We designed 4-month-old APP/PS1 transgenic mice to be treated with intraperitoneal injection of Triagonist, during which urine was collected, often through urinary proteomics to evaluate the therapeutic effect. |
